Neuland Q1 FY27: consolidated PAT jumps 6x YoY to ₹147.7 Cr, margins cool from Q4 peak

Neuland's consolidated Q1 FY27 revenue of ₹641.6 Cr (+119.2% YoY, -17.4% QoQ) and PAT of ₹147.7 Cr (+962% YoY, -30.6% QoQ) came in well above Street estimates of ₹419-482 Cr revenue and ₹18-23 Cr PAT (Univest's Q1 preview) — a clear beat on both lines, though the scale of the YoY jump is exaggerated by an unusually soft Q1 FY26 base (NPM then was just 4.6%, OPM 11.8%). Standalone tracked almost identically — PAT ₹147.4 Cr, EPS ₹114.86 versus ₹115.10 consolidated — so there's no material basis divergence this quarter.

OPM came in at 34.7% and NPM at 22.7%, both sharply higher than a year ago (11.8%/4.6%) but down from Q4 FY26's 39.6%/27.0%. That sequential cooling is exactly what management flagged on the Q4 call, where it explicitly said the Q4 margins were not sustainable and future profitability would hinge on business mix and cost pressures. The expense build was broad-based rather than driven by one line: employee costs rose to ₹106.4 Cr from ₹73.5 Cr YoY and manufacturing expenses to ₹47.9 Cr from ₹39.4 Cr YoY as the topline scaled, while cost of materials grew more slowly (₹228.8 Cr vs ₹161.5 Cr YoY) — some operating leverage even as the margin percentage eased off the Q4 high.

The stock went into the print at ₹20,049, up 6.1% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters.

EPS ₹115.10 consolidated (basic/diluted, not annualised) vs ₹10.83 a year ago and ₹165.76 in Q4 FY26.

Management's only standing guidance is a long-term aspirational 18-20% revenue CAGR, with growth explicitly described as "lumpy, not linear" quarter to quarter — this quarter's sharp QoQ pullback in both revenue and profit is consistent with that framing rather than a red flag, so the print reads as on-guidance. The same day, the board approved a ₹40 Cr corporate guarantee backing a new long-term CDMO partnership with Gland Pharma to build a dedicated sterile API manufacturing suite (~1,400 kg of added annual capacity) at Gland's Vizag facility — CEO Saharsh Davuluri framed it as strengthening Neuland's "differentiated platform" in complex, sterile APIs, tying into the company's stated capital-deployment focus on peptide manufacturing and R&D expansion. The board separately cleared an ₹39.8 Cr, 18 KL capacity addition at Unit 1 (Bonthapally), funded via internal accruals, alongside confirmation that the previously flagged expanded units began production on July 31, 2026.